Zaragoza, Sophia |
| Active, not recruiting | 2/3 | 186 | NA | Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo | Zydus Therapeutics Inc., Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 05/25 | 05/25 | | |
Ruiz, Monica |
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | US, RoW | Saroglitazar Magnesium 1 mg | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 04/27 | 07/27 | | |
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Recruiting | N/A | 150 | US | Dulce Digital Text-Based Education, Project Dulce Telehealth, Project Dulce Live | Scripps Whittier Diabetes Institute | Diabetes Type 2 | 11/24 | 11/24 | | |
Golez, Jerica |
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | US, RoW | Saroglitazar Magnesium 1 mg | Zydus Therapeutics Inc. | Primary Biliary Cholangitis | 04/27 | 07/27 | | |
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis |
|
|
| Active, not recruiting | 1/2 | 42 | US | CNP-104, Placebo | COUR Pharmaceutical Development Company, Inc. | Primary Biliary Cholangitis | 01/26 | 01/26 | | |